our Premium Content: News alerts, weekly reports and conference planners

GENE:

IL32 (Interleukin 32)

News alerts, weekly reports and conference planners

Expression of MicroRNA-155 and its associations with EBV serological markers and inflammatory cytokines in young lymphoma patients with evidence of active EBV infection. (PubMed, Exp Biol Med (Maywood))

These findings indicate that serum miR-155 is significantly elevated in young lymphoma patients with serological evidence of active EBV infection and is statistically associated with inflammatory cytokines, particularly IL-32. miR-155 may represent a promising non-invasive biomarker reflecting EBV-related immune activation, although tissue-based EBV confirmation and mechanistic studies are required to establish causality.

4 days ago

Observational data • Journal

MIR155 (MicroRNA 155) • IL18 (Interleukin 18) • IL32 (Interleukin 32)

10d

Role of IL-32 in RA pathology and potential as a drug target. (PubMed, Front Immunol)

Preclinical studies have demonstrated that genetic or pharmacologic inhibition of IL-32 attenuates experimental arthritis severity, underscoring its therapeutic potential. Herein, we provide a comprehensive, up-to-date review of the current understanding of IL-32 biology in RA and its translational implications.

10 days ago

Review • Journal

TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL32 (Interleukin 32)

28d

Tumor microenvironment-derived IL-32 promotes aggressive phenotypes and stem cell traits in head and neck squamous cell carcinoma. (PubMed, J Dent Sci)

CAFs promote HNSCC progression through IL-32-mediated enhancement of invasion, EMT induction, and CSC properties. Targeting IL-32 signalling may represent a promising therapeutic approach to improve outcomes in HNSCC.

28 days ago

Journal

CDH1 (Cadherin 1) • CD24 (CD24 Molecule) • VIM (Vimentin) • IL32 (Interleukin 32) • SNAI1 (Snail Family Transcriptional Repressor 1)

Development and validation of a diagnostic machine learning model for gastric cancer risk based on double-negative T cell-related features. (PubMed, Cancer Cell Int)

The study established a novel diagnostic model for GC based on DN T cell signature genes, which shows robust predictive performance and significant clinical benefit. The findings underscore the important role of DN T cells and model genes in GC, providing new insights into early diagnosis and potential therapeutic targets for effective management of GC.

1 month ago

Journal

EML4 (EMAP Like 4) • IL32 (Interleukin 32)

Multifaceted role of interleukin-32 in inflammatory diseases and cancer. (PubMed, Biomed Pharmacother)

Nevertheless, a comprehensive understanding of the isoform-specific roles and molecular mechanisms of IL-32 in cancer and inflammatory diseases remains incomplete. Therefore, in this review, we aimed to summarize the current literature on the function of IL-32 in the development of inflammatory diseases and cancer, and discuss potential therapeutic strategies targeting IL-32 through emerging big data analysis.

1 month ago

Review • Journal

IL32 (Interleukin 32)

2ms

A single-cell cytokine dictionary of human peripheral blood. (PubMed, Res Sq)

Finally, we show how the Human Cytokine Dictionary enables the interpretation of cytokine-driven immune responses in other studies and disease contexts, including systemic lupus erythematosus, multiple sclerosis, and non-small cell lung carcinoma. Together, the Human Cytokine Dictionary constitutes the first comprehensive cell type-resolved transcriptional screen of human cytokine responses and provides an essential open-access, easy-to-use community resource with accompanying software package to advance our understanding of cytokine biology in human disease and guide therapeutic discovery.

2 months ago

Journal

IL10 (Interleukin 10) • IL32 (Interleukin 32)

2ms

Enhanced Expression of IL32 mRNA in Skeletal Muscles in the Context of Head and Neck Carcinomas. (PubMed, J Cachexia Sarcopenia Muscle)

IL32 is a potential biomarker for CRS in HNC patients. In addition, the HNC-myoblast co-cultivation model provides a promising in vitro system to study CRS mechanisms, potentially reducing the reliance on animal models.

2 months ago

Journal

BIRC3 (Baculoviral IAP repeat containing 3) • IL32 (Interleukin 32)

2ms

A single-cell cytokine dictionary of human peripheral blood. (PubMed, bioRxiv)

2 months ago

Journal

IL10 (Interleukin 10) • IL32 (Interleukin 32)

3ms

METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells. (PubMed, Cancer Med)

These findings demonstrate, for the first time, that METTL14 modulates the expression of genes related to TNF, IFN, IL, and MHC class I in NPC, proposing a novel role for METTL14 in linking inflammation with cancer, a function that has not been fully elucidated.

3 months ago

Journal

HLA-A (Major Histocompatibility Complex, Class I, A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL7R (Interleukin 7 Receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HLA-B (Major Histocompatibility Complex, Class I, B) • IL32 (Interleukin 32) • CD40LG (CD40 ligand) • IFI16 (Interferon Gamma Inducible Protein 16) • IL1B (Interleukin 1, beta) • IL7 (Interleukin 7) • PSMA2 (Proteasome 20S Subunit Alpha 2) • PSMC6 (Proteasome 26S Subunit, ATPase 6) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • HLA-C (Major Histocompatibility Complex, Class I, C) • METTL14 (Methyltransferase 14) • TNFRSF12A (TNF Receptor Superfamily Member 12A)

3ms

Targeting the HMGB1-IL32 pathway to alleviate T cell exhaustion in epithelial ovarian cancer. (PubMed, Geroscience)

The signaling path from HMGB1 to IL32 revealed NFKB1 as the most significant signaling mediator and TP53 as the most significant transcriptional regulator via which HMGB1 influenced IL32 expression in CD8 + T cells. The HMGB1-IL32 signaling pathway identified in our analysis can serve as a therapy target for a new generation of adjuvant therapy designed to suppress and disrupt tumor cells' influence on the microenvironment and enhance immunotherapy efficiency.

3 months ago

Journal • IO biomarker

TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • HMGB1 (High Mobility Group Box 1) • IL32 (Interleukin 32)

4ms

Subtype-specific NK cell-TAM interactions drive a novel prognostic signature in HNSCC. (PubMed, Front Immunol)

A 23-gene NK-TAM interaction-related signature (CINT) effectively stratified patient risk in both training and validation cohorts (P < 0.05) and predicted survival benefit in immunotherapy-treated patients. This study uncovers subtype-specific NK-TAM interactions in HNSCC and introduces CINT as a robust prognostic and immunotherapy response model, offering a new strategy for immune microenvironment-targeted therapy.

4 months ago

Journal • IO biomarker

CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD163 (CD163 Molecule) • SPP1 (Secreted Phosphoprotein 1) • IL32 (Interleukin 32) • APOE (Apolipoprotein E) • IL1B (Interleukin 1, beta) • ITGB2 (Integrin Subunit Beta 2) • NFKBIA (NFKB Inhibitor Alpha 2) • STMN1 (Stathmin 1)

5ms

Cancer-associated fibroblasts shape the formation of budding cancer cells at the invasive front of human colorectal cancer. (PubMed, Commun Biol)

In addition, we defined an 11-gene signature (TYK2, IL2RG, KRT17, HLA-B, NPPC, WIF1, IL32, B2M, CCND1, CRIP1, ITGB1), which characterizes cancer cells en route to metastasis and is associated with inferior outcomes. Collectively, our findings suggest that CAFs induce pro-invasive gene expression changes involved in EMT, ECM remodeling, and migration.

5 months ago

Journal

CCND1 (Cyclin D1) • B2M (Beta-2-microglobulin) • HLA-B (Major Histocompatibility Complex, Class I, B) • KRT17 (Keratin 17) • TYK2 (Tyrosine Kinase 2) • IL32 (Interleukin 32) • CRIP1 (Cysteine Rich Protein 1) • WIF1 (WNT Inhibitory Factor 1) • ITGB1 (Integrin Subunit Beta 1) • IL2RG (Interleukin 2 Receptor Subunit Gamma)